Immune Thrombocytopenia News and Research

RSS

Analysis of adverse events in older US adults after COVID-19 mRNA vaccination

Researchers evaluated adverse events in older adults after mRNA vaccination for COVID-19.

24 Jan 2023

Study shows potential benefits of efgartigimod as a treatment for immune thrombocytopenia

Patients taking efgartigimod, a drug being studied for use to treat chronic primary immune thrombocytopenia (ITP), exhibited a significantly greater improvement in platelet counts which are essential to clotting and stopping bleeding, compared to those taking a placebo, according to results reported from the ADVANCE IV clinical trial, which was conducted globally, including at Georgetown University Medical Center.

12 Dec 2022

Large COVID vaccination study found that thrombosis and thrombocytopenia are very rare complications

Researchers determine the rates of thrombosis, thrombocytopenia, and thrombosis with thrombocytopenia following COVID-19 vaccination and infection.

28 Nov 2022

U.S. COVID-19 vaccine safety surveillance results for the over 65s

In a recent study posted to the medRxiv* server, researchers conducted near real-time safety monitoring in the United States (US) elderly population for 14 safety outcomes weekly following the coronavirus disease 2019 (COVID-19) vaccination

7 Nov 2022

AstraZeneca COVID-19 vaccine safe and effective in phase 3 U.S., Chile, and Peru trial

A new study reports on the results of phase III clinical trial on the safety and efficacy of the AstraZeneca-Oxford COVID-19 vaccine.

5 Oct 2021

SARS-CoV-2 Spike may trigger production of antibodies that cross-react with human thrombopoietin to induce thrombocytopenia

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infected individuals often suffer from thrombocytopenia, a condition associated with low platelet counts. The cytokine thrombopoietin regulates platelet count. Previous studies have reported that thrombocytopenia can increase the coronavirus disease 2019 (COVID-19) mortality rate by about five times.

16 Aug 2021

Iron chelating properties of eltrombopag in pediatric acute myeloid leukemia

Oncotarget published "Eltrombopag and its iron chelating properties in pediatric acute myeloid leukemia" which reported that the standard treatment for pediatric AML currently consists in a combination of cytarabine and antracycline.

9 Aug 2021

mRNA COVID-19 vaccines may increase patients' concerns about side effects

Vivid photos of the red "COVID arm" rash and reports of facial swelling in patients who have received dermatological fillers after Pfizer-BioNTech or Moderna vaccination for COVID-19 may increase patients' concerns about mRNA vaccine side effects and contribute to vaccine hesitancy.

23 Jun 2021

Little evidence for mRNA COVID-19 vaccine-associated thrombocytopenia, suggests new FDA study

Even as a host of vaccines have been rolled out to counter the coronavirus disease 2019 (COVID-19) pandemic, some serious adverse effects have been reported, in the form of thrombocytopenia. A new study in the journal Vaccine reports the results of an evaluation of reported cases of this condition, using data from the Vaccine Adverse Event Reporting System (VAERS).

24 May 2021

Pfizer-BioNTech vaccination not associated with platelet activation in new study

Among the devastating complications of severe or critical coronavirus disease 2019 (COVID-19), clot formation ranks high in the adverse impact it creates. An important question is whether SARS-CoV-2-spike-based vaccines also cause such coagulopathies. A new study, released as a preprint on the medRxiv* server, examines this risk for the first time.

21 May 2021

Early treatment may prevent clotting in COVID-19 vaccine-related thrombocytopenia

Now, a new report in the Journal of Thrombosis and Hemostasis reveals that timely diagnosis and treatment of this condition may prevent further morbidity and mortality, and enable the vaccine to be used widely with confidence.

20 May 2021

Research says benefits of continuing immunization of front-line workers in BC with AstraZeneca vaccine far outweigh risks

A recent study by researchers at the University of British Columbia (B.C.) shows that the benefits of continuing the COVID-19 vaccine of front-line workers with the AstraZeneca vaccine outweigh the increased risk of prothrombotic thrombocytopenia.

19 Apr 2021

Phase 3 study to test efficacy of new treatment for pediatric acute-onset neuropsychiatric syndrome

Octapharma has launched a phase 3, multi-center superiority study to compare the effectiveness of PANZYGA (immune globulin intravenous, human - ifas) 10% Liquid Preparation versus placebo in patients with pediatric acute-onset neuropsychiatric syndrome (PANS).

3 Sep 2020

Groundbreaking technology could enhance therapeutic efficiency of nanomedicines

Researchers from the Moscow Institute of Physics and Technology and their colleagues from Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry and Prokhorov General Physics Institute of the Russian Academy of Sciences have developed a breakthrough technology to resolve a key problem that has prevented the introduction of novel drugs into clinical practice for decades.

17 Jul 2020

Repurposed drug for acute lung injury in COVID-19

Now, a new study addresses the possible use of an FDA-approved monoclonal antibody, called fostamatinib, a spleen tyrosine kinase inhibitor (SYK), to reduce the levels of mucin-1, a molecule associated with acute lung injury and acute respiratory distress syndrome (ARDS). People who have severe COVID-19 disease may develop ARDS.

2 Jul 2020

Research reveals genetic variants linked to treatment-related complications in children with blood diseases

Research to be presented today at the 57th American Society of Hematology Annual Meeting and Exposition reveals genetic variants that are associated with disease severity and treatment-related complications in children with blood diseases.

7 Dec 2015

Manchester researchers demonstrate safety, effectiveness of eltrombopag treatment in children with ITP

Researchers in Manchester have demonstrated for the first time the relative safety and effectiveness of treatment, eltrombopag, in children with persistent or chronic immune thrombocytopenia (ITP), as part of an international duo of studies.

9 Oct 2015

Novartis receives FDA approval for expanded use of Promacta for younger children with rare blood disorder

Novartis announced today that the US Food and Drug Administration has approved an expanded use for Promacta to include children 1 year of age and older with chronic immune thrombocytopenia who have had an insufficient response to corticosteroids, immunoglobulins or splenectomy.

26 Aug 2015

New study may help identify novel ways to treat immune thrombocytopenia

Immune thrombocytopenia, or ITP, is an autoimmune disease whereby the immune system sends antibodies to attack and destroy the body's platelets--blood cells responsible for controlling bleeding.

20 Jul 2015

Novartis announces FDA approval of Promacta for treatment of children with chronic ITP

Novartis announced today that the US Food and Drug Administration has approved Promacta (eltrombopag) for the treatment of children six years and older with chronic immune thrombocytopenia (ITP) who have had an insufficient response to corticosteroids, immunoglobulins or splenectomy. Promacta was approved by the FDA in 2008 for use in adult patients with the same condition.

15 Jun 2015